S
Staci L. Sudenga
Researcher at Vanderbilt University Medical Center
Publications - 48
Citations - 903
Staci L. Sudenga is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: HPV infection & Population. The author has an hindex of 13, co-authored 44 publications receiving 738 citations. Previous affiliations of Staci L. Sudenga include Vanderbilt University & University of Alabama at Birmingham.
Papers
More filters
Journal ArticleDOI
EUROGIN 2014 roadmap: Differences in human papillomavirus infection natural history, transmission and human papillomavirus‐related cancer incidence by gender and anatomic site of infection
Anna R. Giuliano,Alan G. Nyitray,Aimée R. Kreimer,Christine M. Pierce Campbell,Marc T. Goodman,Staci L. Sudenga,Joseph Monsonego,Silvia Franceschi +7 more
TL;DR: In this paper, differences in HPV-related cancer and infection burden by gender and anatomic site are reviewed, with nearly 100% of cervical, 88% of anal, and <50% of lower genital tract and oropharyngeal cancers attributable to HPV.
Journal ArticleDOI
Knowledge, attitudes, practices, and perceived risk of cervical cancer among Kenyan women: brief report.
TL;DR: Understanding factors associated with women’s perceived risk of cervical cancer could guide future educational and clinical interventions to increase cervical cancer screening in sub-Saharan Africa.
Journal ArticleDOI
Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.
Staci L. Sudenga,Donna J. Ingles,Christine M. Pierce Campbell,Hui-Yi Lin,William J. Fulp,Jane L. Messina,Mark H. Stoler,Martha Abrahamsen,Luisa L. Villa,Eduardo Lazcano-Ponce,Anna R. Giuliano +10 more
TL;DR: Most EGLs develop following infection with HPV 6, 11, or 16, all of which could be prevented with the 4-valent HPV vaccine, according to a prospective analysis nested within the HPV Infection in Men study.
Journal ArticleDOI
The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents
Sadeep Shrestha,Staci L. Sudenga,Jennifer S. Smith,Laura H. Bachmann,Laura H. Bachmann,Craig M. Wilson,Mirjam C. Kempf +6 more
TL;DR: Overall, the incidence and prevalence of HPV types 58, 53/66, 68/70, and 31/33/35 were much higher than the established carcinogenic and HPV vaccine types 16 and 18, especially in HIV-positive females both before and after HAART initiation.
Journal ArticleDOI
Alternative dosage schedules with HPV virus-like particle vaccines
TL;DR: In this paper, a two-dose vaccine schedule was proposed to prevent multiple cancers in women and men, and the data are generally supportive of moving to a 2-dose vaccination schedule among young female adolescents.